Punt C J A
Department of Medical Oncology, University Medical Center St Radboud, Nijmegen, The Netherlands.
Ann Oncol. 2004 Oct;15(10):1453-9. doi: 10.1093/annonc/mdh383.
With more data on the use of oxaliplatin and irinotecan available, and the recent approval of two signal transduction inhibitors for patients with advanced colorectal cancer, there are now many treatment options to choose from. From the current regimens no straightforward choice can be made that provides any patient with the optimal chance for prolonged survival with the least side-effects. The current data concerning timing and duration of chemotherapy, combination or sequential therapy, preference of agents for first-line treatment, oral fluoropyrimidines, neo-adjuvant chemotherapy for irresectable liver metastases, and the use of signal transduction inhibitors are reviewed.
随着更多关于奥沙利铂和伊立替康使用的数据可用，以及最近两种信号转导抑制剂被批准用于晚期结直肠癌患者，现在有许多治疗方案可供选择。从目前的治疗方案中，无法做出直接的选择，为任何患者提供以最少副作用实现延长生存期的最佳机会。本文综述了有关化疗时机和持续时间、联合或序贯治疗、一线治疗药物的选择、口服氟嘧啶、不可切除肝转移的新辅助化疗以及信号转导抑制剂使用的现有数据。
